| Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ... New England Journal of Medicine 373 (3), 220-231, 2015 | 1544 | 2015 |
| Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open … DE Griffith, G Eagle, R Thomson, TR Aksamit, N Hasegawa, K Morimoto, ... American journal of respiratory and critical care medicine 198 (12), 1559-1569, 2018 | 273 | 2018 |
| Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis JD Chalmers, CS Haworth, ML Metersky, MR Loebinger, F Blasi, O Sibila, ... New England Journal of Medicine 383 (22), 2127-2137, 2020 | 222 | 2020 |
| Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial DP Nichols, AC Paynter, SL Heltshe, SH Donaldson, CA Frederick, ... American journal of respiratory and critical care medicine 205 (5), 529-539, 2022 | 212 | 2022 |
| Lactate kinetics in sepsis and septic shock: a review of the literature and rationale for further research J Chertoff, M Chisum, B Garcia, J Lascano Journal of intensive care 3, 1-4, 2015 | 128 | 2015 |
| KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa R Jain, VV Beckett, MW Konstan, FJ Accurso, JL Burns, N Mayer-Hamblett, ... Journal of Cystic Fibrosis 17 (4), 484-491, 2018 | 84 | 2018 |
| A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment CH Goss, SL Heltshe, NE West, M Skalland, DB Sanders, R Jain, TL Barto, ... American journal of respiratory and critical care medicine 204 (11), 1295-1305, 2021 | 61 | 2021 |
| Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT EA Bohula, DD Berg, MS Lopes, JM Connors, I Babar, CF Barnett, ... Circulation 146 (18), 1344-1356, 2022 | 56 | 2022 |
| Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis PA Flume, JP Clancy, GZ Retsch-Bogart, DE Tullis, M Bresnik, ... Journal of Cystic Fibrosis 15 (6), 809-815, 2016 | 55 | 2016 |
| Prognostic utility of plasma lactate measured between 24 and 48 h after initiation of early goal-directed therapy in the management of sepsis, severe sepsis, and septic shock J Chertoff, M Chisum, L Simmons, B King, M Walker, J Lascano Journal of intensive care 4, 1-8, 2016 | 52 | 2016 |
| Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease F Ayoub, C Trillo-Alvarez, G Morelli, J Lascano World Journal of Hepatology 10 (1), 34, 2018 | 43 | 2018 |
| Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND … PA Flume, RF Biner, DG Downey, C Brown, M Jain, R Fischer, ... The Lancet Respiratory Medicine 9 (7), 733-746, 2021 | 40 | 2021 |
| Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study SM Rowe, JB Zuckerman, D Dorgan, J Lascano, K McCoy, M Jain, ... Journal of Cystic Fibrosis 22 (4), 656-664, 2023 | 36 | 2023 |
| Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence ML Brantly, JE Lascano, A Shahmohammadi Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 6 (1 …, 2019 | 36 | 2019 |
| α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy MA Campos, J Lascano Therapeutic advances in respiratory disease 8 (5), 150-161, 2014 | 30 | 2014 |
| Proton pump inhibitor use is associated with an increased frequency of hospitalization in patients with cystic fibrosis F Ayoub, J Lascano, G Morelli Gastroenterology Research 10 (5), 288, 2017 | 28 | 2017 |
| Gender and racial disparities in lung transplantation in the United States LE Riley, J Lascano The Journal of Heart and Lung Transplantation 40 (9), 963-969, 2021 | 25 | 2021 |
| Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial DP Nichols, PK Singh, A Baines, LJ Caverly, JF Chmiel, RL GIbson, ... Thorax 77 (6), 581-588, 2022 | 22 | 2022 |
| CFTR modulator use in post lung transplant recipients LA Benninger, C Trillo, J Lascano The Journal of Heart and Lung Transplantation 40 (12), 1498-1501, 2021 | 22 | 2021 |
| The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency JE Lascano, MA Campos Postgraduate medicine 129 (8), 889-895, 2017 | 19 | 2017 |
